Grupo de genetica y epigenetica de enfermedades complejas
Hospital Universitario La Paz
Madrid, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Universitario La Paz (32)
2024
2023
-
Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders
Blood, Vol. 142, Núm. 5, pp. 434-445
2022
-
Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish children
European journal of pediatrics, Vol. 181, Núm. 3, pp. 1105-1115
-
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 809-815
-
Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice
Anales de Pediatria, Vol. 97, Núm. 2, pp. 130.e1-130.e7
-
Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries – A study by the Joint Action on Rare Cancers
Cancer Epidemiology, Vol. 78
-
Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
British Journal of Clinical Pharmacology, Vol. 88, Núm. 9, pp. 4220-4223
2021
2020
-
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic
Pediatric Blood and Cancer
-
Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia
Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955
-
Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia
BMJ Open, Vol. 10, Núm. 1
2018
-
Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk
Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914
-
Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment
Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412
-
Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia
Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712
-
Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity
Epigenomics, Vol. 10, Núm. 4, pp. 409-417
2017
-
Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population
PLoS ONE, Vol. 12, Núm. 5
-
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Journal of Pediatrics, Vol. 189, pp. 72-78.e3
-
Early clinical trials in paediatric oncology in Spain: a nationwide perspective
Anales de Pediatria, Vol. 87, Núm. 3, pp. 155-163
2016
-
A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility
Pediatric Research, Vol. 80, Núm. 4, pp. 472-479
-
High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study
Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307